Veitch, Zachary W.
Cescon, David W.
Denny, Trisha
Yonemoto, Lisa-Maria
Fletcher, Graham
Brokx, Richard
Sampson, Peter
Li, Sze-Wan
Pugh, Trevor J.
Bruce, Jeffrey
Bray, Mark R.
Slamon, Dennis J.
Mak, Tak W.
Wainberg, Zev A.
Bedard, Philippe L.
Funding for this research was provided by:
Princess Margaret Cancer Foundation
California Institute for Regenerative Medicine
Article History
Received: 4 April 2019
Revised: 17 June 2019
Accepted: 20 June 2019
First Online: 15 July 2019
Competing interests
: CFI-400945 is a proprietary compound developed at the Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre/University Health Network, with which Z.W.V., D.W.C., S.-W.L., T.D., G.F., R.B., P.S., T.J.P., J.B., M.R.B., T.W.M., and P.L.B. are affiliated. D.W.C. has provided a consulting or advisory role for Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Merck, Roche/Genentech, Agendia, and Puma Biotechnology. He has also received research funding from Merck, GlaxoSmithKline, and Pfizer. In addition, he has a patent pending for Biomarkers of TTK inhibitors. P.L.B. has received research funding from Bristol-Myers Squibb, Sanofi, AstraZeneca, Genentech/Roche, SERVIER, GlaxoSmithKline, Novartis, SignalChem, PTC Therapeutics, Nektar, Merck, Seattle Genetics, Mersana, Immunomedics, and Eli-Lilly. Z.A.W. has performed consulting services for Merck, Lilly, BMS, Five Prime, and Novartis. D.J.S. currently holds board membership for Biomarin and is compensated for travel and accommodation expenses. He also holds stock in Pfizer and is provided research funding and compensated for travel and accommodations. He also receives honoraria from Novartis in addition to providing consulting/advisory services, receiving research funding, and is compensated for travel and accommodations. He also provides a general consulting and advisory role for Eli Lily Pharmaceuticals. M.R.B. and T.W.M. are shareholders in a company that has an option agreement for CFI-400945. T.W.M. has performed consulting services for Symphogen, CASI, Sanofi, and Agios. He is also a stockholder in Agios. L.-M.Y. declares no competing interests.
: This study protocol (NCT01954316) was approved by local institutional review boards (Princess Margaret Cancer Centre - Ontario Cancer Research Ethics Board [OCREB] - #13-050; OHRPP – Office of the Human Research Protection Program - #13-001872) of the two participating institutions and adhered to Good Clinical Practice (GCP) guidelines, the Declaration of Helsinki, and local laws. All patients provided written informed consent prior to initiation of study procedures.
: This work was supported by Princess Margaret Cancer Foundation (PMCF) and California Institute of Regenerative Medicine (CIRM) – Disease Team Research Award.
: All patients provided written informed consent prior to initiation of study procedures. This includes, as per the patient Informed Consent Form (ICF), consent for publication of aggregate data. No identifying patient details, images, or videos are used in this manuscript.
: The data sets generated duration and/or analysed during the current study are not publicly available due to patient privacy laws (Personal Information Protection and Electronic Documents Act [PIPEDA]) but are available from the corresponding author on reasonable request.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).